ClinicalTrials.gg
CompletedNCT01160211Updated Mar 7, 2025Results posted

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

A Phase 3 interventional study of Lapatinib and Trastuzumab in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 110 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
13th of 114
369 · median 35
Started
2011
with 7 others
Phase 3
18 of 114
none open now
Registered
81st of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 13th largest by enrollment, is one of 8 that started in 2011, is one of 18 in phase 3, and was the 81st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).

Read the detailed description

This Phase III, multicenter, open-label study randomized subjects to one of the three treatment arms:

  1. Treatment group A: lapatinib 1000 mg PO once daily + trastuzumab (loading dose of 8 mg/kg) followed by the maintenance dose of 6 mg/kg IV q3weeks + an AI (either letrozole, anastrozole, or exemestane) of Investigator's choice PO once daily.
  2. Treatment group B: trastuzumab (loading dose of 8 mg/kg) followed by maintenance dose of 6 mg/kg IV q3weeks + an AI (either letrozole, anastrozole, or exemestane) of Investigator's choice PO once daily.
  3. Treatment group C: lapatinib 1500 mg PO once daily + an AI (either letrozole, anastrozole, or exemestane) of Investigator's choice PO once daily.

Treatment continued until disease progression, death, or unacceptable toxicities, whichever came first.

Subjects who discontinued study treatment for reasons other than disease progression were followed-up every 12 weeks until disease progression or death, until the start of post-study treatment anti-cancer therapy (including radiotherapy and surgery), withdrawal of consent, or lost to follow-up, whichever came first.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • 1st line MBC
  • MBC
  • hormone receptor positive
  • lapatinib
  • trastuzumab
  • HER2 positive
  • aromatase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrollment in the study must meet all of the following criteria:

  1. Signed written . In Korea and Japan, subjects between >=18 and \<20 years of age must also have a legal representative sign the written informed consent.
  2. female subjects >=18 years of age. Post-menopausal as defined by any of the following:

    • Subjects at least 60 years of age.
    • Subjects under 60 years of age and amenorrhic for at least 12 consecutive months AND follicle-stimulating hormone (FSH) and estradiol levels in postmenopausal range (utilizing ranges from the local laboratory facility).
    • Prior bilateral oophorectomy.
    • Prior radiation castration with amenorrhea for at least 6 months
  3. Subjects must have a history of confirmed breast cancer, with a clinically confirmed diagnosis of disease [confirmed by histology, cytology or other clinical means (e.g. CT, MRI)]. Subjects may have either measurable or non- per (RECIST 1.1)
  4. Tumors that are ER+ and/or PgR+ by local laboratory
  5. Documentation of overexpression or gene amplification, in the invasive component of either the primary tumor or metastatic disease site as defined as:

    • 3+ by Immunohistochemistry (IHC) and/or
    • HER2/neu gene amplification by fluorescence, chromogenic or silver in situ hybridization [FISH, CISH or SISH; >6 HER2/neu gene copies per nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals) of ≥2.0]
  6. Subject must have received at least one prior regimen containing trastuzumab in combination with chemotherapy for breast cancer:.

    • Subject has ONLY received prior trastuzumab in combination with chemotherapy as and/or adjuvant treatment. OR
    • Subject has received ONE prior trastuzumab-containing regimen for metastatic disease (and has progressed), and may or may not have received prior trastuzumab in combination with chemotherapy as neoadjuvant and/or adjuvant treatment.
  7. Subject must have received prior endocrine therapy (such as aromatase inhibitors or selective estrogen receptor modulators). 8. Subjects who have a of > 6 months as assessed by the treating investigator
  1. Subjects must have baseline (LVEF) ≥50% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA) 10. Subject must have an performance status of 0-1 11. All prior treatment related toxicities must be (Version 4.0) ≤ Grade 1 at the time of randomization 12. Completion of screening assessments 13. Adequate baseline organ function. 14. Subjects must meet all of the following criteria:
  • \<450msec or
  • QTc \<480msec for subjects with bundle branch block The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB) or to Fridericia's formula (QTcF), machine or manual over read, for males and females. The specific formula that will be used in a protocol should be determined prior to initiation of the study, and the formula used to determine inclusion and discontinuation should be the same throughout the study. The QTc should be based on single or averaged QTc values of triplicate (ECGs) obtained over a brief recording period

Exclusion criteria

Exclusion criteria:

  1. History of another . Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
  2. Subjects with extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor, or the disease is considered by the investigator to be rapidly progressing or life threatening (subjects who are intended for chemotherapy)
  3. Serious cardiac illness or medical condition including but not confined to:

    • Uncontrolled arrhythmias
    • Uncontrolled or symptomatic angina
    • History of congestive heart failure (CHF)
    • Documented myocardial infarction \<6 months from study entry
  4. Known history of, or clinical evidence of, central nervous system (CNS) or
  5. Have acute or currently active/requiring anti-viral therapy hepatic or biliary disease (with the exception of subjects with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  6. Have a concurrent disease or condition that may interfere with study participation, or any serious medical disorder that would interfere with the subject's safety (for example, active or uncontrolled infection or any psychiatric condition prohibiting understanding or rendering of )
  7. Have any gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
  8. Have a known immediate or delayed reaction or idiosyncrasy to drugs chemically related to any of the study agents or their that, in the opinion of the Investigator or GSK medical monitor, contraindicates their participation
  9. Any prohibited medication.
  10. Administration of an drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Lapatinib 1000 mg PO once daily + Trastuzumab (loading dose of 8 mg/kg) followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks) + an Aromatase Inhibitor (AI) of Investigator's choice PO once daily.

    Drug: Lapatinib · Drug: Trastuzumab · Drug: Aromatase Inhibitor

  • Active comparator
    Treatment group B

    Trastuzumab (loading dose of 8 mg/kg) followed by maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks) + an Aromatase Inhibitor (AI) of Investigator's choice PO once daily.

    Drug: Trastuzumab · Drug: Aromatase Inhibitor

  • Active comparator
    Treatment Group C

    Lapatinib 1500 mg PO once daily + an Aromatase Inhibitor (AI) of Investigator's choice PO once daily.

    Drug: Aromatase Inhibitor · Drug: Lapatinib

Interventions

  • 1000 mg by mouth once a day

  • Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks)

  • Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily

  • 1500 mg by mouth once daily

This study also gives Anastrozole, Exemestane. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)

    The Number of Participants with Progression free survival (PFS) events in the Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) arm vs. Trastuzumab + Aromatase Inhibitor (AI) arm was based on assessments by the Investigator.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years

  2. Median Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)

    Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 11 years

  2. Overall Survival (OS)

    The Number of Participants with Overall Survival (OS) events was based on assessments by the Investigator.

    Time frame: From date of randomization until date of death from any cause, assessed up approximately 11 years

  3. Overall Response Rate (ORR)

    Overall Response Rate (ORR) was defined as the proportion of participants achieving either a Complete Response (CR) or Partial Response (PR). The ORR was calculated from the Investigator's assessment of response based on RECIST 1.1. Subjects with an unknown or missing response were treated as non-responders; i.e. they were included in the denominator when calculating the percentages. Subjects who do not have measurable disease contributed to the Response Rate based analyses, for the evaluation of CR, SD and PD.

    Time frame: Up approximately 11 years

  4. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) was defined as the percentage of patients with evidence of Complete Response (CR), Partial Response (PR), or maintaining Stable Disease (SD) for at least 6 months while on study, according to the investigator assessment of response per RECIST 1.1 criteria.

    Time frame: Up approximately 11 years

  5. Time to Response

    Time to Response (TTR) was defined as the time from randomization to the earliest date of Complete Response (CR) or Partial Response (PR)

    Time frame: From date of randomization until the earliest date of Complete Response (CR) or Partial Response (PR), assessed up approximately 11 years

  6. Duration of Response (DoR)

    Duration of Response (DOR) was defined as the duration between the date of first documented Complete Response (CR) or Partial Response (PR) and the date of first documented sign of Progressive Disease or Death, or to the date of censor.

    Time frame: From first documented evidence of CR or PR (the response prior to confirmation) until time of documented disease progression or death due to any cause, whichever comes first, assessed up approximately 11 years

  7. Mean Change in the Quality of Life (QoL) Status Relative to Baseline FACT-B Overall and Subscale Scores at Last On Treatment Assessment

    Quality of life was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire. It is a 37-item (27 general questions and 10 breast cancer specific questions) self-reporting instrument consisting of 5 dimensions: physical well-being (PWB), social well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and a breast cancer subscale (BCS). The followings were the score ranges for each self-reporting subscale: • PWB : 0-28 • SWB : 0-28 • EWB : 0-24 • FWB : 0-28 • BCS : 0-40 FACT-B Total Outcome Index (TOI) = PWB + FWB + BCS (range:0 - 96) FACT-B Total Score = PWB + SWB + EWB + FWB + BCS (range:0-148) FACT-G Total Score = PWB + SWB + EWB + FWB (range:0-108). For all the FACIT scales and symptom indices, the higher the score the better QoL

    Time frame: Day 1 (pre-dose), up approximately 11 years

07

Results

Posted Jul 15, 2019

Participant flow

This study was conducted at 113 centers in 29 countries worldwide (Argentina, Australia, Belgium, Brazil, Bulgaria, China, Croatia, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Peru, Poland, Portugal, Republic of Korea, Russia, Serbia, Singapore, Spain, Taiwan, Turkey, UK, Ukraine and USA)

Participant flow — Overall Study
MilestoneLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Started124123122
Safety set123123121
Completed646455
Not completed605967
Withdrew: Subject reached protocol-defined stopping criteria494959
Withdrew: Lost to follow-up484
Withdrew: Physician decision100
Withdrew: Withdrawal by subject422
Withdrew: Data unavailable due to regulatory issues202

Outcome measures

PrimaryProgression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)

The Number of Participants with Progression free survival (PFS) events in the Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) arm vs. Trastuzumab + Aromatase Inhibitor (AI) arm was based on assessments by the Investigator.

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years
Reported as:
Count of participants · Participants
Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)
ParticipantsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Disease progression or died (event)6275
Censored, follow-up for disease progression ended73
Censored, f/p for disease progression ongoing5139
Statistical analysis
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Log Rank · p = 0.0063 (Pike estimate of the treatment hazard ratio, \<1 indicates a lower risk compared with trastuzumab + AI.) · Hazard ratio (hr): 0.62 · 95% CI 0.45 to 0.88using a two-sided stratified log-rank test (based on stratification factors)
PrimaryMedian Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)

Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years
Reported as:
Median · Months
Median Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)
MonthsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Median Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)11.0 (8.3 to 13.8)5.6 (5.4 to 8.3)
SecondaryProgression Free Survival (PFS)

Progression free survival (PFS) was defined as the interval of time between the date of randomization and the earliest date of disease progression (with radiological evidence) or death from any cause, or to the date of censor. Disease progression was based on assessments by the Investigator.

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 11 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Progression Free Survival (PFS)11.1 (10.0 to 15.3)8.3 (7.1 to 11.0)5.7 (5.5 to 8.3)
Statistical analysis
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Hazard ratio (hr): 0.59 · 95% CI 0.44 to 0.79
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Hazard ratio (hr): 0.87 · 95% CI 0.66 to 1.15
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Lapatinib + Aromatase Inhibitor (AI) · Hazard ratio (hr): 0.68 · 95% CI 0.51 to 0.92
SecondaryOverall Survival (OS)

The Number of Participants with Overall Survival (OS) events was based on assessments by the Investigator.

Time frame:
From date of randomization until date of death from any cause, assessed up approximately 11 years
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Death384539
Censored, follow-up ended867883
Censored, follow-up ongoing000
SecondaryOverall Response Rate (ORR)

Overall Response Rate (ORR) was defined as the proportion of participants achieving either a Complete Response (CR) or Partial Response (PR). The ORR was calculated from the Investigator's assessment of response based on RECIST 1.1. Subjects with an unknown or missing response were treated as non-responders; i.e. they were included in the denominator when calculating the percentages. Subjects who do not have measurable disease contributed to the Response Rate based analyses, for the evaluation of CR, SD and PD.

Time frame:
Up approximately 11 years
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Overall Response Rate (ORR)32.3 (24.2 to 41.2)22.8 (15.7 to 31.2)17.2 (11.0 to 25.1)
SecondaryClinical Benefit Rate (CBR)

Clinical Benefit Rate (CBR) was defined as the percentage of patients with evidence of Complete Response (CR), Partial Response (PR), or maintaining Stable Disease (SD) for at least 6 months while on study, according to the investigator assessment of response per RECIST 1.1 criteria.

Time frame:
Up approximately 11 years
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate (CBR)
Percentage of ParticipantsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Clinical Benefit Rate (CBR)51.6 (42.5 to 60.7)43.1 (34.2 to 52.3)34.4 (26.1 to 43.6)
SecondaryTime to Response

Time to Response (TTR) was defined as the time from randomization to the earliest date of Complete Response (CR) or Partial Response (PR)

Time frame:
From date of randomization until the earliest date of Complete Response (CR) or Partial Response (PR), assessed up approximately 11 years
Reported as:
Median · Days
Time to Response
DaysLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Time to Response85.0 (72 to 1031)86.5 (65 to 1175)86.0 (67 to 337)
SecondaryDuration of Response (DoR)

Duration of Response (DOR) was defined as the duration between the date of first documented Complete Response (CR) or Partial Response (PR) and the date of first documented sign of Progressive Disease or Death, or to the date of censor.

Time frame:
From first documented evidence of CR or PR (the response prior to confirmation) until time of documented disease progression or death due to any cause, whichever comes first, assessed up approximately 11 years
Reported as:
Median · Months
Duration of Response (DoR)
MonthsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Duration of Response (DoR)22.5 (11.1 to 33.1)11.1 (5.6 to NA)11.8 (5.4 to 28.1)
SecondaryMean Change in the Quality of Life (QoL) Status Relative to Baseline FACT-B Overall and Subscale Scores at Last On Treatment Assessment

Quality of life was assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire. It is a 37-item (27 general questions and 10 breast cancer specific questions) self-reporting instrument consisting of 5 dimensions: physical well-being (PWB), social well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and a breast cancer subscale (BCS). The followings were the score ranges for each self-reporting subscale: • PWB : 0-28 • SWB : 0-28 • EWB : 0-24 • FWB : 0-28 • BCS : 0-40 FACT-B Total Outcome Index (TOI) = PWB + FWB + BCS (range:0 - 96) FACT-B Total Score = PWB + SWB + EWB + FWB + BCS (range:0-148) FACT-G Total Score = PWB + SWB + EWB + FWB (range:0-108). For all the FACIT scales and symptom indices, the higher the score the better QoL

Time frame:
Day 1 (pre-dose), up approximately 11 years
Reported as:
Least squares mean · score on a scale
Mean Change in the Quality of Life (QoL) Status Relative to Baseline FACT-B Overall and Subscale Scores at Last On Treatment Assessment
score on a scaleLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
FACT-B total score-4.2 ± 1.48-6.3 ± 1.51-2.4 ± 1.51
FACT-G total score-4.3 ± 1.22-5.9 ± 1.24-2.8 ± 1.24
FACT-B trial outcome Index (TOI)-3.3 ± 1.05-4.2 ± 1.07-0.6 ± 1.07
Physical well-being (PWB)-2.0 ± 0.48-2.1 ± 0.49-0.5 ± 0.49
Social family wellbeing (SWB)-0.5 ± 0.50-1.5 ± 0.50-0.9 ± 0.51
Emotional wellbeing (EWB)-0.4 ± 0.40-0.6 ± 0.40-1.0 ± 0.41
Functional wellbeing (FWB)-1.3 ± 0.45-1.7 ± 0.46-0.3 ± 0.46
Breast cancer subscale (BCS)0.0 ± 0.47-0.5 ± 0.470.4 ± 0.48
Statistical analysis
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -1.79 · 95% CI -5.95 to 2.36
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -3.90 · 95% CI -8.09 to 0.29
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -1.50 · 95% CI -4.92 to 1.92
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -3.10 · 95% CI -6.55 to 0.34
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -2.70 · 95% CI -5.66 to 0.25
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -3.61 · 95% CI -6.59 to -0.64
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -1.46 · 95% CI -2.82 to -0.11
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -1.54 · 95% CI -2.90 to -0.18
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: 0.39 · 95% CI -1.01 to 1.79
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -0.55 · 95% CI -1.96 to 0.86
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: 0.54 · 95% CI -0.57 to 1.66
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: 0.40 · 95% CI -0.72 to 1.53
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -0.99 · 95% CI -2.26 to 0.28
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -1.32 · 95% CI -2.60 to -0.04
  • Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -0.35 · 95% CI -1.66 to 0.95
  • Lapatinib + Aromatase Inhibitor (AI) vs Trastuzumab + Aromatase Inhibitor (AI) · Least square difference: -0.83 · 95% CI -2.14 to 0.48
Post-hocAll Collected Deaths

Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication. On-treatment deaths were collected from first dose of study medication to 30 days after last dose of study medication (on-treatment), up to approximately 131 months. Deaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approximately 132 months.

Time frame:
Pre-treatment deaths: Up to 28 days prior to treatment. On-treatment deaths: Up to 131 months. Post-treatment deaths: up to 132 months.
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)
Pre-treatment deaths000
On-treatment deaths585
Post-treatment deaths333734
All deaths384539

Adverse events

Collected over Adverse Events (AEs) were collected from first dose of study medication until the last dose plus 30 days post-treat follow-up, assessed up to approximately 131 months. Deaths were recorded from study start date until end of survival follow-up phase (end of study), assessed up to approximately 132 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)5/124 (4%)27/123 (22%)113/123 (91.9%)
Lapatinib + Aromatase Inhibitor (AI)8/123 (6.5%)23/123 (18.7%)107/123 (87%)
Trastuzumab + Aromatase Inhibitor (AI)5/122 (4.1%)14/121 (11.6%)86/121 (71.1%)
Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment)33/118 (28%)——
Lapatinib + Aromatase Inhibitor (AI) (Post-treatment)37/114 (32.5%)——
Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment)34/116 (29.3%)——
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment)Lapatinib + Aromatase Inhibitor (AI) (Post-treatment)Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment)
Ejection fraction decreasedInvestigations7/1231/1232/121———
CellulitisInfections and infestations3/1231/1232/121———
Urinary tract infectionInfections and infestations2/1230/1231/121———
HypokalaemiaMetabolism and nutrition disorders2/1230/1230/121———
Cardiac failureCardiac disorders1/1230/1231/121———
Cardio-respiratory arrestCardiac disorders0/1230/1231/121———
AstheniaGeneral disorders0/1230/1231/121———
AppendicitisInfections and infestations0/1230/1231/121———
HypercalcaemiaMetabolism and nutrition disorders0/1230/1231/121———
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1230/1231/121———
Most frequent other events
Showing 10 of 46
Most frequent other events
EventLapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment)Lapatinib + Aromatase Inhibitor (AI) (Post-treatment)Trastuzumab + Aromatase Inhibitor (AI) (Post-treatment)
DiarrhoeaGastrointestinal disorders87/12364/12311/121———
RashSkin and subcutaneous tissue disorders43/12336/1233/121———
ParonychiaInfections and infestations39/12321/1230/121———
NauseaGastrointestinal disorders28/12328/12313/121———
StomatitisGastrointestinal disorders23/12316/1235/121———
Aspartate aminotransferase increasedInvestigations11/12322/12311/121———
Decreased appetiteMetabolism and nutrition disorders22/12318/1234/121———
ArthralgiaMusculoskeletal and connective tissue disorders22/12319/12315/121———
HeadacheNervous system disorders9/12321/12315/121———
Alanine aminotransferase increasedInvestigations11/12320/1239/121———

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)Total
Mean56.9 ± 11.1557.1 ± 9.9854.9 ± 10.1056.3 ± 10.45
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)Total
Female124123122369
Male0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)Lapatinib + Aromatase Inhibitor (AI)Trastuzumab + Aromatase Inhibitor (AI)Total
American Indian or Alaska Native1113
Asian31313294
Native Hawaiian or Other Pacific Islander0000
Black or African American34310
White898584258
More than one race0224
Unknown or Not Reported0000
08

Study locations

110 sites
  • Novartis Investigative Site
    Hollywood, Florida 33021, United States
  • Novartis Investigative Site
    Augusta, Georgia 30912, United States
  • Novartis Investigative Site
    Germantown, Tennessee 38138, United States
  • Novartis Investigative Site
    Tacoma, Washington 98405, United States
  • Novartis Investigative Site
    Berazategui, Buenos Aires B1880BBF, Argentina
  • Novartis Investigative Site
    Capital Federal, Buenos Aires C1417DTN, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1050AAK, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1280AEB, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1920CMK, Argentina
  • Novartis Investigative Site
    Viedma, Río Negro R8500ACE, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000KZE, Argentina
  • Novartis Investigative Site
    Cordoba, X5004FHP, Argentina
  • Novartis Investigative Site
    La Rioja, F5300COE, Argentina
  • Novartis Investigative Site
    Quilmes, 1878, Argentina
  • Novartis Investigative Site
    San Miguel de Tucuman, T4000IAK, Argentina
  • Novartis Investigative Site
    Albury, 2640, Australia
  • Novartis Investigative Site
    Douglas, 4814, Australia
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Namur, 5000, Belgium
  • Novartis Investigative Site
    Goiania, Goiás 74605-070, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90470-340, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 91350-200, Brazil
  • Novartis Investigative Site
    Barretos, São Paulo 14784-400, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 01317-001, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 03102-002, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 05651-901, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, 20560-120, Brazil
  • Novartis Investigative Site
    Plovdiv, 4004, Bulgaria
  • Novartis Investigative Site
    Sofia, 1330, Bulgaria
  • Novartis Investigative Site
    Sofia, 1756, Bulgaria
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Fuzhou, Fujian 350001, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510060, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Harbin, 150081, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Osijek, 31000, Croatia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Besancon, 25030, France
  • Novartis Investigative Site
    Montpellier Cedex 5, 34298, France
  • Novartis Investigative Site
    Paris Cedex 20, 75970, France
  • Novartis Investigative Site
    Muenchen, Bayern 81675, Germany
  • Novartis Investigative Site
    Furstenwalde, Brandenburg 15517, Germany
  • Novartis Investigative Site
    Goslar, Niedersachsen 38642, Germany
  • Novartis Investigative Site
    Troisdorf, Nordrhein-Westfalen 53840, Germany
  • Novartis Investigative Site
    Velbert, Nordrhein-Westfalen 42551, Germany
  • Novartis Investigative Site
    Alexandroupolis, 68100, Greece
  • Novartis Investigative Site
    Chania, 73100, Greece
  • Novartis Investigative Site
    Heraklion, 71110, Greece
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Kowloon, Hong Kong
  • Novartis Investigative Site
    Tuen Mun, Hong Kong
  • Novartis Investigative Site
    Gyor, H-9024, Hungary
  • Novartis Investigative Site
    Gyula, 5700, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Miskolc, 3526, Hungary
  • Novartis Investigative Site
    Nyiregyhaza, 4400, Hungary
  • Novartis Investigative Site
    Pecs, 7624, Hungary
  • Novartis Investigative Site
    Szeged, 6720, Hungary
  • Novartis Investigative Site
    Zalaegerszeg, H-8900, Hungary
  • Novartis Investigative Site
    Nagpur, 440010, India
  • Novartis Investigative Site
    New Delhi, 110 092, India
  • Novartis Investigative Site
    Haifa, 31096, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Rozzano (MI), Lombardia 20089, Italy
  • Novartis Investigative Site
    Aichi, 464-8681, Japan
  • Novartis Investigative Site
    Chiba, 277-8577, Japan
  • Novartis Investigative Site
    Ehime, 791-0280, Japan
  • Novartis Investigative Site
    Osaka, 537-8511, Japan
  • Novartis Investigative Site
    Osaka, 540-0006, Japan
  • Novartis Investigative Site
    Saitama, 362-0806, Japan
  • Novartis Investigative Site
    Tokyo, 104-8560, Japan
  • Novartis Investigative Site
    Gyeonggi-do, 10408, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Arequipa, Peru
  • Novartis Investigative Site
    Lima, Lima 18, Peru
  • Novartis Investigative Site
    Konin, 62-500, Poland
  • Novartis Investigative Site
    Warszawa, 04-125, Poland
  • Novartis Investigative Site
    Lisbon, 1400-038, Portugal
  • Novartis Investigative Site
    Porto, 4200-072, Portugal
  • Novartis Investigative Site
    Arkhangelsk, 163045, Russian Federation
  • Novartis Investigative Site
    Kazan, 420029, Russian Federation
  • Novartis Investigative Site
    Moscow, 115478, Russian Federation
  • Novartis Investigative Site
    Ryazan, 390011, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197758, Russian Federation
  • Novartis Investigative Site
    Belgrade, 11000, Serbia
  • Novartis Investigative Site
    Sremska Kamenica, 21204, Serbia
  • Novartis Investigative Site
    Singapore, 308433, Singapore
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Castellon, 12002, Spain
  • Novartis Investigative Site
    La Coruna, 15009, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Changhua, 500, Taiwan
  • Novartis Investigative Site
    Kaohsiung, 833, Taiwan
  • Novartis Investigative Site
    Taipei City, 11217, Taiwan
  • Novartis Investigative Site
    Ankara, 06200, Turkey

Showing the first 100 of 110 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. J Clin Oncol. 2018 Mar 10;36(8):741-748. doi: 10.1200/JCO.2017.74.7824. Epub 2017 Dec 15. PubMed 29244528 ↗
  • Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol. 2021 Jan 1;39(1):79-89. doi: 10.1200/JCO.20.01894. Epub 2020 Aug 21. PubMed 32822287 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Mar 2016, 58 months.

Results were first posted in Jul 2019, 3 years 4 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 58 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2010
First posted
Jul 12, 2010
StartActual
May 5, 2011
Primary completionActual
Mar 11, 2016
CompletionActual
Jun 6, 2022
Results first posted
Jul 15, 2019
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01160211
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 12, 2010
Start date
May 5, 2011
Primary completion
Mar 11, 2016
Completion
Jun 6, 2022
Results posted
Jul 15, 2019
Last update
Mar 7, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Trastuzumab

Start the discussion